Gastrointestinal Health

Latest News

Diet, Nutrition, GLP-1, Weight Loss | Image Credit: aamulya | stock.adobe.com

Study Reports Dietary Recommendation for Managing GLP-1-Related Gastrointestinal Adverse Events

By Ashley Gallagher, Editor

January 20th 2025

Recommendations help influence the rate of gastric emptying, improve compliance, and prevent interruption of weight loss for patients.

Model of digestive tract with Crohn disease -- Image credit: Jo Panuwat D | stock.adobe.com

FDA Approves Mirikizumab-Mrkz to Treat Adult Patients With Crohn Disease

By Gillian McGovern, Associate Editor

January 16th 2025

This is mirikizumab’s second FDA-approved indication in inflammatory bowel disease.

FDA headquarters -- Image credit: JHVEPhoto | stock.adobe.com

Prucalopride Tablets for Chronic Idiopathic Constipation Launches, Approved for 180-Day CGT Designation

By Gillian McGovern, Associate Editor

January 7th 2025

The tablets are indicated for treatment of adults with chronic idiopathic constipation, with further research needed to assess efficacy and safety in children.

Optimizing Inflammatory Bowel Disease Management: The Value of Integrated Pharmacists in Modern Health Care

By Tori L. Fournier, BSc

January 3rd 2025

Adherence to thiopurine medications after 6 months of use was 87.9% under direct pharmacist care but 65.7% under general practitioner guidance.

fda approved label. fda approved red band sign. fda approved - Image credit: Aquir | stock.adobe.com

Ustekinumab-stba Receives FDA Approval for Autoimmune Disorder and Inflammatory Bowel Disease

By Kennedy Ferruggia, Assistant Editor

December 18th 2024

Ustekinumab-stba (Steqeyma; Celltrion) is a subcutaneous treatment for adult and pediatric patients with plaque psoriasis arthritis, psoriatic arthritis, Crohn disease, and ulcerative colitis.

<1 2 3 4 5 6

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777